Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.
종목 코드 SGHT
회사 이름Sight Sciences Inc
상장일Jul 15, 2021
CEOMr. Paul Badawi
직원 수216
유형Ordinary Share
회계 연도 종료Jul 15
주소4040 Campbell Ave,
도시MENLO PARK
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호94025
전화14158890550
웹사이트https://www.sightsciences.com/
종목 코드 SGHT
상장일Jul 15, 2021
CEOMr. Paul Badawi
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음